New Amsterdam Pharmaceuticals

Cardiovascular disease remains the leading cause of death, disability, and healthcare economic burden worldwide and as such remains the leading population health challenge of our age. Management of LDL-C or “bad cholesterol” is among the most cost-effective and impactful preventative interventions. While statins have had an enormous impact, tens of millions of patients on maximally tolerated statin therapy fail to reach LDL-C targets each year leading to millions of preventable cardiovascular events. Recently offered injectable add-on therapies have thus far failed to scale. New Amsterdam Pharmaceuticals is developing a tablet which has shown a 50% reduction in LDL-C on top of statins in mid-stage clinical trials.